Suppr超能文献

三种抗生素组合加潜在抗生物膜剂对生物膜形成菌和临床分离株的体外作用

In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing and Clinical Isolates.

作者信息

Batista Sara, Fernandez-Pittol Mariana, Nicolás Lorena San, Martínez Diego, Rubio Marc, Garrigo Montserrat, Vila Jordi, Tudó Griselda, González-Martin Julian

机构信息

Unitat de Microbiologia, Department de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.

ISGlobal Barcelona, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain.

出版信息

Antibiotics (Basel). 2023 Sep 6;12(9):1409. doi: 10.3390/antibiotics12091409.

Abstract

Patients with chronic pulmonary diseases infected by complex (MAC) often develop complications and suffer from treatment failure due to biofilm formation. There is a lack of correlation between in vitro susceptibility tests and the treatment of clinical isolates producing biofilm. We performed susceptibility tests of 10 different three-drug combinations, including two recommended in the guidelines, in biofilm forms of eight MAC clinical isolates. Biofilm developed in the eight isolates following incubation of the inoculum for 3 weeks. Then, the biofilm was treated with three-drug combinations with and without the addition of potential antibiofilm agents (PAAs). Biofilm bactericidal concentrations (BBCs) were determined using the Vizion lector system. All selected drug combinations showed synergistic activity, reducing BBC values compared to those treated with single drugs, but BBC values remained high enough to treat patients. However, with the addition of PAAs, the BBCs steadily decreased, achieving similar values to the combinations in planktonic forms and showing synergistic activity in all the combinations and in both species. In conclusion, three-drug combinations with PAAs showed synergistic activity in biofilm forms of MAC isolates. Our results suggest the need for clinical studies introducing PAAs combined with antibiotics for the treatment of patients with pulmonary diseases infected by MAC.

摘要

患有由鸟分枝杆菌复合体(MAC)感染的慢性肺部疾病的患者,常常会因生物膜形成而出现并发症并遭遇治疗失败。体外药敏试验与产生生物膜的临床分离株的治疗之间缺乏相关性。我们对10种不同的三联药物组合进行了药敏试验,其中包括指南中推荐的两种组合,受试对象为8株MAC临床分离株的生物膜形式。接种物培养3周后,8株分离株中形成了生物膜。然后,用添加和不添加潜在抗生物膜剂(PAA)的三联药物组合处理生物膜。使用Vizion读数系统测定生物膜杀菌浓度(BBC)。所有选定的药物组合均显示出协同活性,与单药处理相比,BBC值降低,但BBC值仍高到足以治疗患者。然而,添加PAA后,BBC稳步下降,达到与浮游形式组合相似的值,并在所有组合和两个菌种中均显示出协同活性。总之,含PAA的三联药物组合在MAC分离株的生物膜形式中显示出协同活性。我们的结果表明,需要开展临床研究,引入PAA联合抗生素来治疗MAC感染的肺部疾病患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/261b/10526108/cf799cdc0212/antibiotics-12-01409-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验